CHRYSO
9.9.2020 15:12:38 CEST | Business Wire | Press release
CHRYSO, a world leader in construction chemicals, today announces its partnership with Solidia Technologies, a start-up inventor of revolutionary technology for green cement and concrete. The two companies will collaborate to improve the sustainability performance and material properties of Solidia® ultra-low CO2 concrete through their combined chemical expertise.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200909005655/en/
The partnership is underpinned by a long-term commitment from both companies to making sustainable solutions accessible to cement and concrete producers worldwide.
Solidia®
sustainable technology is already available in the precast market and used for non-reinforced concrete elements. Solidia’s unique technologies are based on a revolutionary cement chemistry that can be produced at lower energies, significantly lowering carbon emissions, and that does not hydrate but carbonates by injection of CO2
into fresh concrete. Combined, Solidia’s processes lower the carbon footprint of concrete by up to 70%, while reducing water and energy consumption. They also improve the performance and durability of concrete, which are further enhanced with new, sophisticated admixture solution.
CHRYSO
draws on a solid knowledge of sustainable building materials. For more than 10 years, the company has been developing admixture solutions that allow the intensive use of alternative binders without compromising material performance.
“The development of innovative admixture solutions adapted to Solidia’s new binder, boosting the final properties of concrete, is one of our R&D works in progress. This will enable higher strengths, an improved finish of the fresh concrete, and the optimization of the curing process. Together with Solidia, we will scale the use of low CO2 concrete, helping manufacturers produce high quality precast elements,” declared Jean Mascaro, Concrete BU director of CHRYSO.
Tom Schuler, president and CEO of Solidia
Technologies
, said: “Incorporating CHRYSO®
’s exclusive water-reducing admixtures adapted to the specific chemistry of Solidia Concrete™, will further reduce water consumption in the curing process.”
A key objective for the start-up is to improve cement and concrete production and performance while enhancing its environmental impact. Tom Schuler
added: “By cutting energy consumption during the curing process, CHRYSO will help us achieve our ambitions and reach higher levels of performance.”
This partnership paves the way for upcoming advances in CO 2 footprint reduction and new developments in sustainable chemistry. The deployment of new ultra-low C0 2 concrete will accelerate the decarbonization of the construction industry.
About the CHRYSO Group
Aimed at cement manufacturers, ready-mix concrete and precast industrials, and construction companies, CHRYSO's offer includes cement additives, concrete admixtures and Solutions for Construction Systems (waterproofing solutions, mortars, etc.). CHRYSO®
solutions have won renown on the most prestigious construction sites throughout the world thanks to the group's extensive network, which includes 22 foreign subsidiaries and covers more than 100 countries through its wide network of distributors, licensees and agents. The CHRYSO group employs over 1,300 staff worldwide. Innovation, customer service, expertise and technical know-how are the CHRYSO Group's cornerstones. More info about CHRYSO: www.chryso.com
About Solidia Technolgies
Solidia Technologies®
is a cement and concrete technology company that makes it easy and profitable to use CO2
to manufacture superior, sustainable building materials. Each year, Solidia can eliminate at least 1.5 Gt of CO₂, save 3 trillion liters of fresh water, reduce cement industry energy consumption by 67 Mt of coal, and eliminate 100 Mt of concrete waste landfill. Produced using the same raw materials and existing equipment, Solidia products are higher performing and cost less to produce than traditional concrete, and cure in less than 24 hours. Solidia offers a rapid, globally scalable response to one of the greatest threats to our planet.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005655/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
